

Quarterly Statement as of March 31, 2021

Financial Highlights Q1/2021

- Group revenues at 229 mEUR, up 25 % compared to prior year quarter
- Good organic revenue growth at 4.9 %
- Recurring revenue share increases slightly to 69 %
- 7% increase in adjusted EBITDA to 47 mEUR
- EBITDA margin of 20 % as planned below prior year due to investments in growth
- Strong Free Cash flow with 70 mEUR above expectations (incl. one-time effects)
- Adjusted earnings per share at 0.33 EUR (prior year: 0.34 EUR)

Financial key figures

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|-------------------------------------|-----------------------|-----------------------|---------|
| Revenues | 228,937 | 183,143 | +25% |
| Recurring Revenues in % | 69% | 67% | +2ppt |
| Organic growth in % | 4.9% | 1.6% | +3.3ppt |
| EBITDA adjusted | 46,531 | 43,477 | +7% |
| EBITDA adjusted margin | 20% | 24% | -4ppt |
| EPS adjusted (EUR) - diluted | 0.33 | 0.34 | -3% |
| CAPEX | 13,414 | 14,681 | -9% |
| Free Cash flow | 70,405 | 51,038 | +38% |
| Number of shares outstanding ('000) | 53,114 | 48,413 | |

NOTICES

Unless otherwise stated, all information and explanatory notes in this report refer to the first quarter of 2021 and 2020, i.e. the three-month period January 1 - March 31 (Q1) and all percentage changes to the respective prior-year comparison. Due to rounding, totals and percentages presented in this report may not add up precisely to the totals provided.

BUSINESS DEVELOPMENT - SIGNIFICANT EVENTS

COVID-19-pandemic

Providing the best possible support to our customers while at the same time ensuring comprehensive protection for employee's remains at the forefront of the activities of CompuGroup Medical (CGM) during the COVID-19-pandemic. In the first quarter CompuGroup Medical initiated further specific measures to support the customers in the COVID-19-pandemic in Germany, Austria, France, Spain, Czech Republic, Italy, Belgium, Netherlands, Sweden, Denmark, and Norway, especially:

- Since March 2021, CGM offers in Germany, initially free of charge for all CGM customers, the vaccination management solution ImpfDocNE as an integrated module for the practice software. The software module supports medical practices with documenting, creating and tracking of vaccination schedules as well as billing.
- In Austria, the "e-vaccination passport" has been offered since January to enable the digital documentation of influenza and COVID-19 vaccinations. The vaccinations are recorded quickly and easily via the patient file directly in the practice software.
- In Italy, COVID-19 vaccinations can now also be administered in pharmacies. CGM supports pharmacies in this process by providing CLICKDOC Farmacie free of charge. This will allow pharmacies to have a smooth vaccination process when organizing and planning.
- In France a module for monitoring the administration of vaccinations is being used

We continue to expect a significantly increased growth opportunity in the medium term due to the increased sustainable willingness to use digital networking solutions in healthcare as a result of the pandemic.

Additional growth through acquisitions

In the first quarter, the foundation was laid for the successful realignment of the US business. The integration of eMDs and Schuyler House, acquired at the end of 2020, into the existing US activities has started. The main products of eMDs are physician information systems and outsourcing services for medical billing. Schuyler House focuses on the Physician Office Lab (POL), small to medium-sized hospitals, clinics and independent as well reference laboratories.

In addition, CompuGroup Medical plans to strengthen its position in France with the acquisition of the Aatlanta Group. With its "Acteur" product, the Aatlanta Group is a leader in the field of physician information systems for health centers. The transaction is expected to be completed by the end of the second quarter.

Hospital Future Act

In the first quarter, numerous customer inquiries were received in connection with the Hospital Future Act ("Krankenhauszukunftsgesetz"). Intensive exchanges on eligible projects have taken place with a large number of customers. The Hospital Future Act was passed in November 2020 and intends to drive digitization in German hospitals in the next years.

Large order for CGM Clinical

The University Medical Center Hamburg-Eppendorf (UKE), Europe's first fully digital hospital with approximately 13,500 employees, selected all CGM CLINICAL Suite solutions after a two-year Europe-wide tender process. The project is scheduled to start in May 2021 with a duration of four years and the common goal of a first live operation in 2022.

Telematics Infrastructure: Pharmacy rollout successfully continued

As part of the Telematics Infrastructure the rollout to pharmacies was successfully continued. Since the start of the rollout the CGM connector has been installed at about 6,000 pharmacies.

Digital health applications are becoming established

The Digital health applications (DiGA's or "Apps on prescription") were introduced in November 2020 and are establishing themselves as an integral part of standard care for physicians and health insurers. These applications can be enacted by the physicians free of charge via the "APP-VERORDNUNGSCENTER" developed by CGM. Patients can redeem the prescribed apps via the CLICKDOC Health Center.

Share buyback

CompuGroup Medical conducted a share buyback program from February 26 to April 29, 2021. The buyback of shares via the stock exchange (Xetra trading on the Frankfurt Stock Exchange) is performed by a mandated securities bank. With this CompuGroup Medical made use of the authorization given by the Annual General Meeting on May 15, 2019, to repurchase treasury shares. During the period between February 26 and April 29, 2021, 1,000,000 shares in total have been repurchased at an average rate of EUR 71.25. In the first quarter, a total of 620,667 shares have been purchased at an average rate of EUR 69.80.

Top score for CGM apprenticeship

Capital magazine and Ausbildung.de has awarded CompuGroup Medical five out of five stars, making it one of the best apprenticing companies in Germany in 2020. With 22 out of a maximum of 25 achievable points, CompuGroup Medical performs excellently in Germany.

Change of leadership in the Executive Board

On January 1, 2021, Dr. Dirk Wössner took over the CEO position from the company's founder and long-time CEO Frank Gotthardt (now Chairman of the Board of Directors). Dirk Wössner was a member of the Management Board of Deutsche Telekom AG until 2020, where he had been responsible for the German business since January 1, 2018. Prior to that, he had been responsible for the mobile and cable business with residential customers at the Canadian market leader Rogers Communications since 2015. From 2002 to 2015, he held various management positions at Deutsche Telekom in Germany and England.

EARNINGS DEVELOPMENT IN THE GROUP

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|--|-----------------------|-----------------------|
| Revenues | 228,937 | 183,143 |
| Capitalized inhouse services and other income | 10,264 | 9,795 |
| Expenses for goods and services purchased | -41,452 | -32,170 |
| Personnel expenses | -114,481 | -89,607 |
| Other expenses and net impairment losses on financial and contract assets | -38,896 | -31,050 |
| EBITDA | 44,372 | 40,110 |
| Depreciation of property, plant and equipment, right-of-use assets and amortization of intangible assets | -26,823 | -16,782 |
| EBIT | 17,549 | 23,328 |
| Financial result | -1,469 | -4,519 |
| EBT | 16,080 | 18,809 |
| Income taxes for the period | -5,081 | -5,976 |
| CONSOLIDATED NET INCOME FOR THE PERIOD | 10,999 | 12,833 |

Compared to the same quarter of last year revenues in the first quarter increased by mEUR 45.8 (25 %) to mEUR 228.9. Organic growth in the first quarter of 2021 amounts to 4.9 % compared to prior year, which is mainly due to higher revenues in connection with the pharmacy rollout within Telematics Infrastructure. Excluding the revenue growth of the Telematics Infrastructure, organic growth amounts to 1.5 % in the quarter.

Adjusted consolidated earnings before interest, taxes, depreciation, and amortization (adjusted Group EBITDA) for the first quarter of 2021 amounts to mEUR 46.5 (prior year: mEUR 43.5) with an adjusted EBITDA margin of 20 % (prior year: 24 %). The margin decrease is due to the announced investments in further growth.

Adjusted Group EBITDA is derived from reported EBITDA as shown below:

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|--|-----------------------|-----------------------|
| EBITDA REPORTED | 44,372 | 40,110 |
| Adjustments: | | |
| M&A Transactions | 73 | 2,953 |
| Share-based option programs | 2,086 | 461 |
| Restructuring program expenses | 0 | 0 |
| Other non-operative, extraordinary or one-time effects | 0 | -47 |
| EBITDA ADJUSTED | 46,531 | 43,477 |

The main developments in operating expenses are:

- The cost of purchased goods and services increased by mEUR 9.3 compared to prior year. This is mainly due to increased expenses from acquisitions amounting to mEUR 8.5. The gross margin ((revenues less cost of services purchased) / revenues) remains with 82 % at the level of the prior year.
- Personnel expenses increased by 28 % to mEUR 114.5 compared to prior year (prior year: mEUR 89.6). Directors' remuneration, which is no longer reported under personnel expenses due to the change in legal form (now other expenses), was more than offset by new hires in research and development, general wage and salary increases and acquisitions which accounted for mEUR 18.2, or 20 %.
- Other expenses, including impairment losses on financial assets and contract assets, are mEUR 7.8 higher than in prior year and amount to mEUR 38.9. This is mainly due to higher expenses for server maintenance and the reclassification of directors' compensation to other expenses after changing the Company's legal form.

Depreciation of property, plant and equipment and rights of use assets amount to mEUR 8.3 in the first quarter and hence are by mEUR 0.9 above the prior year's figure (prior year: mEUR: 7,4). Amortization of intangible assets in the first quarter increased by mEUR 9.1 to mEUR 18.5 (prior year: mEUR 9.4), primarily due to higher amortization from purchase price allocations for company acquisitions and self-developed software.

Financial income decrease from mEUR 0.6 in the first quarter of 2020 to mEUR 0.2 in the first quarter of the current year, mainly due to interest income from issued loans.

Financial expenses are composed as follows:

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|---|-----------------------|-----------------------|
| Interest and expenses on loans and financial services | 1,278 | 3,140 |
| Changes in purchase price liabilities | 410 | 136 |
| Exchange rate losses on internal liabilities in foreign currency | 85 | 1,377 |
| Capitalized interest on qualifying assets under construction (IAS 23) | -176 | -208 |
| Other | 43 | 91 |
| TOTAL | 1,640 | 4,536 |

In the first quarter of 2021, consolidated net income amounts to mEUR 11.0 compared to mEUR 12.8 in the prior year period. The Group tax rate for the first quarter is 31.6 % compared to 31.8 % in the first quarter of last year.

Adjusted earnings per share are as follows:

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|--|-----------------------|-----------------------|
| CONSOLIDATED NET INCOME OF THE PERIOD (ALLOCATED TO SHAREHOLDERS OF THE PARENT COMPANY) | 10,975 | 12,692 |
| Adjustments: | | |
| M&A Transactions | 5,600 | 3,243 |
| Share-based option programs | 1,910 | 323 |
| Restructuring program expenses | 0 | 0 |
| Other non-operative, extraordinary or one-time effects | 0 | 768 |
| ADJUSTED CONSOLIDATED NET INCOME FOR THE PERIOD (ALLOCATED TO SHAREHOLDERS OF THE PARENT COMPANY) | 18,485 | 17,026 |
| ADJUSTED UNDILUTED EARNINGS PER SHARE (IN EUR) | 0.34 | 0.35 |
| ADJUSTED DILUTED EARNINGS PER SHARE (IN EUR) | 0.33 | 0.34 |
| weighted average of outstanding shares acc. to IAS 33 - undiluted ('000)* | 53,626 | 48,413 |
| weighted average of outstanding shares acc. to IAS 33 - diluted ('000)* | 56,056 | 49,413 |

* Weighted average number of outstanding shares for the quarter calculated from the earnings per shares for the quarter

EARNINGS DEVELOPMENT OF THE BUSINESS SEGMENTS

Ambulatory Information Systems (AIS)

| mEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|-----------------------------|-----------------------|-----------------------|--------|
| Revenues to third parties | 112.2 | 95.1 | 18% |
| thereof organic revenues* | 93.8 | 95.1 | -1% |
| Share of recurring revenues | 77% | 73% | |
| EBITDA adjusted | 29.7 | 27.2 | 9% |
| in % of revenues | 26% | 29% | |

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- The software business with physicians and dentists generated revenues of mEUR 112.2 in the first quarter 2021, which represents an increase of 18 % compared to the prior year. This increase in the first quarter of 2021 is attributable to acquisitions, mainly eMDs in the US.
- Inorganic effects contributed with mEUR 18.4 to the revenues in the first quarter of 2021.
- Organic revenue development was with - 1 % slightly below the prior year. This revenue development is mainly due to a strong first quarter of 2020, which was supported by the Windows 10 launch.
- Recurring revenues in the AIS segment have increased by 25 % to mEUR 86.9.
- At mEUR 29.7, adjusted EBITDA is 9 % higher than the first quarter of the prior year. The EBITDA margin declined because of increased investments in development activities as well as the newly acquired US business.

Hospital Information Systems (HIS)

| mEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|-----------------------------|-----------------------|-----------------------|--------|
| Revenues to third parties | 55.1 | 33.7 | 64% |
| thereof organic revenues* | 36.5 | 33.7 | 8% |
| Share of recurring revenues | 68% | 65% | |
| EBITDA adjusted | 7.6 | 4.2 | 80% |
| in % of revenues | 14% | 13% | |

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- The strong revenue growth in the HIS segment of 64 % is mainly due to the acquisition of the IT healthcare portfolio from Cerner Corporation at the end of the second quarter 2020.
- Adjusted for inorganic revenues of mEUR 18.6, organic growth stood at 8 %. The positive organic growth in the first quarter is attributable to a good development in the German clinic business.
- Recurring revenues increased by 73 % to mEUR 37.5 mostly due to acquisitions.
- Adjusted EBITDA of mEUR 7.6 is well above prior year's figure of mEUR 4.2. The EBITDA margin is slightly above prior year despite increased investments in growth.

Consumer and Health Management Information Systems (CHS)

| mEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|-----------------------------|-----------------------|-----------------------|--------|
| Revenues to third parties | 33.7 | 25.4 | 33% |
| thereof organic revenues* | 34.0 | 25.4 | 34% |
| Share of recurring revenues | 43% | 50% | |
| EBITDA adjusted | 5.2 | 4.9 | 6% |
| in % of revenues | 15% | 19% | |

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- CHS segment revenues increase by 33 % to mEUR 33.7.
- Adjusted for inorganic effects, organic revenue growth of 34 % resulted mostly from the Telematics Infrastructure rollout to pharmacies. Adjusted for the growth of the Telematics Infrastructure, organic growth amounted to 9 %, mostly driven by the data business (Intermedix).
- Adjusted EBITDA of mEUR 5.2 is 6 % above the prior year. The EBITDA margin was below the prior year and mainly influenced by higher hardware revenues related to the ongoing pharmacy rollout of the Telematics Infrastructure and increased investments in growth.

Pharmacy Information Systems (PCS)

| mEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|-----------------------------|-----------------------|-----------------------|--------|
| Revenues to third parties | 27.9 | 28.8 | -3% |
| thereof organic revenues* | 27.9 | 28.8 | -3% |
| Share of recurring revenues | 71% | 67% | |
| EBITDA adjusted | 8.0 | 8.9 | -10% |
| in % of revenues | 29% | 31% | |

* Adjusted for revenues of companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- The pharmacy software business generated revenues of mEUR 27.9 in the first quarter of 2021, thereby - 3 % below the prior year. The strong prior year quarter was positively affected by the launch of Windows 10.
- Recurring revenues in the PCS segment increase by 3 % to mEUR 19.8 compared to the same period last year.
- Adjusted EBITDA of mEUR 8.0 is below prior year's result of mEUR 8.9. The EBITDA margin decreased due to increased investments.

Other segments and consolidation

| mEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Change |
|------------------------|-----------------------|-----------------------|--------|
| Sales to third parties | 0.0 | 0.2 | -100% |
| EBITDA adjusted | -4.0 | -1.8 | -125% |

- Adjusted EBITDA in other segments and consolidation is mEUR 2.2 below prior year. The EBITDA decreased due to growth investments in personnel.
- Adjusted one-time effects in this segment for the first quarter of 2021 mainly comprise of additional costs related to the stock option program in the amount of mEUR 2.1. The first quarter of 2020 includes adjusted one-time effects totaling mEUR 3.6.

Staff Development

| Staff Development | 31.03.2021 | 31.03.2020 | 31.12.2020 |
|--|------------|------------|------------|
| Number of employees (HC) | 7,976 | 5,795 | 7,814 |
| thereof from acquisitions at time of acquisition | 19 | 36 | 1,832 |
| Full-time equivalent (FTE)* | 7,534 | 5,405 | 7,384 |

* FTE: Indicates for a number of real jobs with different time models the number of notional full-time jobs with the same work capacity.

Headcount increased by 162 compared to year end 2020, of which 19 employees resulted from acquisitions. The number of FTEs increased by 150 compared to the end of the year. The majority of the new hires took place in research and development as well as in product management and sales.

NET ASSETS OF THE GROUP

| kEUR | 31.03.2021 | | 31.12.2020 | | Changes | |
|---------------------|------------------|-------------|------------------|-------------|---------------|-----------|
| Non-current assets | 1,260,278 | 78% | 1,257,662 | 80% | 2,616 | 0% |
| Current assets | 351,845 | 22% | 308,110 | 20% | 43,735 | 14% |
| TOTAL ASSETS | 1,612,123 | 100% | 1,565,772 | 100% | 46,351 | 3% |

| kEUR | 31.03.2021 | | 31.12.2020 | | Changes | |
|--------------------------|------------------|-------------|------------------|-------------|---------------|-----------|
| Equity | 620,115 | 38% | 638,937 | 41% | -18,822 | -3% |
| Non-current liabilities | 605,316 | 38% | 636,300 | 40% | -30,984 | -5% |
| Current liabilities | 386,692 | 24% | 290,535 | 19% | 96,157 | 33% |
| TOTAL LIABILITIES | 1,612,123 | 100% | 1,565,772 | 100% | 46,351 | 3% |

CGM's total assets increase by 3 % as of March 31, 2021, which corresponds to an increase of mEUR 46.4 to mEUR 1,612.1 (December 31, 2020: mEUR 1,565.8).

Significant changes in assets are:

- Increase in rights of use by mEUR 4.4 to mEUR 48.9, mainly due to new lease agreements and extension of existing real estate lease agreements.
- Decrease in inventories by mEUR 3.5 to mEUR 14.6. Inventories mainly comprise merchandise for CGM's hardware and peripheral equipment trading business as well as components of the Telematics Infrastructure.

- Increase of trade receivables by mEUR 20.0 to mEUR 157.2, mainly due to a high level of receivables from maintenance contracts invoiced in the first quarter, which are expected to be settled in the second quarter of 2021.
- Increase in current other non-financial assets by mEUR 14.6 to mEUR 39.0. This is mainly coming from prepaid expenses and an increase in the VAT surplus.
- Increase in cash and cash equivalents from mEUR 75.9 at the end of 2020 by mEUR 12.9 to mEUR 88.8. The increase in cash and cash equivalents is mainly due to the strong increase in Free Cash flow in the first quarter of 2021.

All other assets are subject to only minor changes in absolute terms in the first quarter of 2021.

The Group's equity decreased from mEUR 638.9 as of December 31, 2020 to mEUR 620.1 as of March 31, 2021. The change in equity results from the repurchase of treasury shares in the first quarter of 2021 and, in the opposite direction, from net income.

Current and non-current liabilities are subject to the following significant changes compared to year-end 2020:

- Current and non-current liabilities to banks decreased by mEUR 10.2 from mEUR 496.4 to mEUR 486.2 due to repayment of loans.
- Current contract liabilities increased by mEUR 66.7 from mEUR 63.9 to mEUR 130.6. This increase is primarily related to seasonal prepayments for software maintenance contracts.
- Trade payables decreased by mEUR 10.7 from mEUR 64.5 to mEUR 53.8 in the reporting period due to the invoicing process.
- Other current non-financial liabilities increased by mEUR 13.7 to mEUR 35.4, mainly due to an increase in VAT liabilities.

All other current and non-current liabilities are subject to only minor changes in the first quarter of 2021.

FINANCIAL POSITION OF THE GROUP

The liquidity situation and financial position of CGM are shown in the following condensed Cash flow statement and key figures on debt:

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | Changes |
|--|-----------------------|-----------------------|---------|
| OPERATING CASH FLOW | 83,819 | 65,719 | 18,100 |
| CASH FLOW FROM INVESTING ACTIVITIES | -14,583 | -23,987 | 9,404 |
| FREE CASH FLOW | 70,405 | 51,038 | 19,367 |
| CASH FLOW FROM FINANCING ACTIVITIES | -57,259 | -27,398 | -29,861 |
| CHANGE IN CASH AND CASH EQUIVALENTS | 11,977 | 14,334 | -2,357 |
| Changes due to exchange rate fluctuations | 953 | -1,603 | 2,556 |
| Cash and cash equivalents at the beginning of the period | 75,910 | 46,350 | 29,560 |
| CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 88,840 | 59,081 | 29,759 |
| NET DEBT* | 459,871 | 428,301 | 31,570 |
| LEVERAGE (LTM)** | 1.99 | 2.17 | |

* Liabilities to banks (incl. leasing liabilities according to IFRS 16) ./ cash and cash equivalents (with the exception of accounts under third-party management)

** Net debt / EBITDA adjusted/pro forma (LTM) plus pro rata EBITDA of newly acquired companies

In the first quarter of 2021, Free Cash flow amounts to mEUR 70.4 compared to mEUR 51.0 in the same period of the prior year. The positive development of the Free Cash flow in the reporting period results from the harmonization of the bonuses payments across the Group, which were paid in 2021 at the beginning of the following quarter, less investments in fixed assets, and an improved working capital management.

The derivation of Free Cash flow is shown below:

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|---|-----------------------|-----------------------|
| OPERATING CASH FLOW | 83,819 | 65,719 |
| CASH FLOW FROM INVESTING ACTIVITIES | -14,583 | -23,987 |
| ./. Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods) | 1,169 | 7,819 |
| ./. Cash outflow for acquisitions from prior periods | 0 | 1,487 |
| FREE CASH FLOW | 70,405 | 51,038 |

Cash flow from investing activities amounts to mEUR -14.6 in the first quarter of 2021, compared to mEUR -24.0 in the same period of the previous year.

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 |
|---|-----------------------|-----------------------|
| Company acquisition | -1,169 | -7,819 |
| Purchase of minority interest and past acquisition | 0 | -1,487 |
| Capitalized in-house services and other intangible assets | -9,249 | -9,006 |
| Joint ventures and other equity investments | 0 | 0 |
| Office building and property | -172 | -2,909 |
| Other property and equipment | -3,993 | -2,766 |
| Sale of subsidiaries and business operations | 0 | 0 |
| TOTAL | -14,583 | -23,987 |

Cash flow from financing activities amount to mEUR -57.3 in the first quarter of 2021 (prior year: mEUR 27.4). The mEUR 29.9 higher cash outflows from Cash flow from financing activities compared to prior year are primarily due to the purchase of treasury shares with mEUR 41.3. This was offset by lower repayments of debt in the comparative period.

As of March 31, 2021, cash and cash equivalents amount to mEUR 88.8 (prior year: mEUR 59.1). The reported cash and cash equivalents also include restricted cash and cash equivalents.

Net debt at reporting date March 31, 2021, amounts to mEUR 459.9 and thus is mEUR 20.0 lower than the net debt at December 31, 2020, of mEUR 479.9. The leverage is 1.99 (December 31, 2020: 2.04) and thus fulfills the requirements of the existing loan agreement.

GUIDANCE FOR CGM GROUP

Group

Guidance for financial year 2021 remains unchanged since publication on February 4, 2021.

For 2021, CGM expects unchanged revenues in a range of mEUR 1,000 to mEUR 1,040, corresponding to revenue growth of 19 % to 24 %.

Recurring revenues are expected to be above 60 %.

Organic growth is expected between 4 % and 8 %.

Adjusted EBITDA is expected in a range of mEUR 210 to mEUR 230.

Adjusted earnings per share (diluted) are expected to be between EUR 1.70 and EUR 1.95.

Capex is expected to be in the range of mEUR 70 to mEUR 80.

Free Cash flow is expected to be above mEUR 80.

Segments

- AIS revenues are expected to be in the range of mEUR 485 to mEUR 500.
- The PCS segment is expected to generate revenues of mEUR 115 to mEUR 120.
- Revenues for the HIS segment are expected to be in the range of mEUR 240 to mEUR 250.
- The CHS segment is expected to generate revenues between mEUR 160 and mEUR 170 in 2020.

The above guidance for the current financial year was prepared in January 2021 and does not consider any effects from currently pending acquisitions and potential transactions in the course of the financial year 2021. The guidance for 2021 represents management's best estimate of future market conditions and the development of CompuGroup Medical's business segments in this environment and may be affected in particular by delays in the implementation of the Telematics Infrastructure for which the Company is not responsible. In addition, the further impact of the global COVID-19-pandemic cannot be fully assessed. The 2021 guidance could also be influenced by exchange rate effects (in particular changes in the U.S. dollar exchange rate against the Euro).

CompuGroup has been reporting adjusted key figures for the operating result (EBITDA) and earnings per share since the financial year 2020. These key figures are not defined under International Financial Reporting Standards (IFRS) and should be regarded as supplementary information. Adjusted EBITDA and adjusted earnings per share exclude effects from major acquisition and disposal of subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), impairment losses and write-ups on investments, effects from the acquisition, construction and disposal of real estate, impairment losses and write-ups on owner-occupied property, as well as expenses in connection with share-based payment programs for Managing Directors, taxes attributable to the above effects and other non-operating or non-periodic non-recurring effects.

Interim Statement of Financial Position

as of March 31, 2021

ASSETS

| kEUR | 31.03.2021 | 31.03.2020 | 31.12.2020 |
|---|------------------|------------------|------------------|
| Non-current assets | | | |
| Intangible assets | 1,086,237 | 670,731 | 1,088,105 |
| Property, plant and equipment | 92,250 | 90,545 | 91,739 |
| Right-of-use assets | 48,913 | 40,612 | 44,552 |
| Investments in associates and joint ventures (valued at-equity) | 2,001 | 334 | 2,001 |
| Other investments | 641 | 1,993 | 640 |
| Finance lease receivables | 13,448 | 14,934 | 14,169 |
| Contract assets | 26 | 0 | 36 |
| Other financial assets | 10,070 | 9,291 | 10,267 |
| Other non-financial assets | 1,200 | 1,200 | 1,200 |
| Deferred taxes | 5,492 | 6,181 | 4,953 |
| | 1,260,278 | 835,821 | 1,257,662 |
| Current assets | | | |
| Inventories | 14,612 | 29,575 | 18,158 |
| Trade receivables | 157,183 | 125,672 | 137,203 |
| Finance lease receivables | 9,584 | 7,859 | 9,686 |
| Contract assets | 26,175 | 10,916 | 23,433 |
| Other financial assets | 1,139 | 2,334 | 2,663 |
| Other non-financial assets | 38,998 | 27,615 | 24,405 |
| Income tax receivables | 15,314 | 10,288 | 16,652 |
| Cash & cash equivalents | 88,840 | 59,081 | 75,910 |
| | 351,845 | 270,340 | 308,110 |
| | 1,612,123 | 1,109,161 | 1,565,772 |

SHAREHOLDER EQUITY AND LIABILITIES

| kEUR | 31.03.2021 | 31.03.2020 | 31.12.2020 |
|---|------------------|------------------|------------------|
| Equity | | | |
| Subscribed capital | 53,735 | 53,219 | 53,735 |
| Treasury shares | -43,388 | -86,322 | 0 |
| Reserves | 609,474 | 303,022 | 584,932 |
| Capital and reserves allocated to the shareholders of the parent company | 619,821 | 269,919 | 638,667 |
| Non-controlling interests | 294 | 307 | 270 |
| | 620,115 | 270,226 | 638,937 |
| Non-current liabilities | | | |
| Provisions for post-employment benefits and other non-current provisions | 43,356 | 30,802 | 43,707 |
| Liabilities to banks | 428,839 | 408,158 | 461,061 |
| Contract liabilities | 7,268 | 5,220 | 6,628 |
| Purchase price liabilities | 3,819 | 7,353 | 3,780 |
| Lease liabilities | 29,267 | 26,040 | 27,989 |
| Other financial liabilities | 8,030 | 12,533 | 9,144 |
| Other non-financial liabilities | 1,200 | 1,192 | 1,200 |
| Deferred taxes | 83,537 | 71,258 | 82,791 |
| | 605,316 | 562,556 | 636,300 |
| Current liabilities | | | |
| Liabilities to banks | 57,336 | 19,688 | 35,298 |
| Contract liabilities | 130,564 | 108,697 | 63,894 |
| Purchase price liabilities | 13,379 | 8,271 | 12,078 |
| Trade payables | 53,792 | 38,776 | 64,524 |
| Income tax liabilities | 12,747 | 14,325 | 19,364 |
| Other provisions | 52,566 | 38,316 | 47,277 |
| Lease liabilities | 19,477 | 14,082 | 16,576 |
| Other financial liabilities | 11,406 | 7,458 | 9,837 |
| Other non-financial liabilities | 35,425 | 26,765 | 21,687 |
| | 386,692 | 276,378 | 290,535 |
| | 1,612,123 | 1,109,161 | 1,565,772 |

Interim Income Statement

for the reporting period of January 1, – March 31, 2021

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | 01.01.- 31.12.2020 |
|--|-----------------------|-----------------------|-----------------------|
| Revenues | 228,937 | 183,143 | 837,259 |
| Capitalized inhouse services | 7,877 | 8,022 | 31,872 |
| Other income | 2,387 | 1,773 | 10,562 |
| Expenses for goods and services purchased | -41,452 | -32,170 | -156,178 |
| Personnel expenses | -114,481 | -89,607 | -377,052 |
| Net impairment losses on financial and contract assets | -871 | -921 | -4,292 |
| Other expenses | -38,025 | -30,130 | -144,695 |
| Earnings before interest, taxes, depreciation and amortization (EBITDA) | 44,372 | 40,110 | 197,476 |
| Depreciation of property, plant and equipment and right-of-use assets | -8,288 | -7,397 | -30,856 |
| Earnings before interest, taxes and amortization (EBITA) | 36,084 | 32,713 | 166,620 |
| Amortization of intangible assets | -18,535 | -9,385 | -44,851 |
| Earnings before interest and taxes (EBIT) | 17,549 | 23,328 | 121,769 |
| Result from companies accounted for using the equity method | 11 | -603 | -931 |
| Financial income | 160 | 620 | 2,651 |
| Financial expenses | -1,640 | -4,536 | -13,063 |
| Earnings before taxes (EBT) | 16,080 | 18,809 | 110,426 |
| Income taxes for the period | -5,081 | -5,976 | -37,006 |
| Results from continued operations | 10,999 | 12,833 | 73,420 |
| Profit for the period from discontinued operations | 0 | 0 | 0 |
| Consolidated net income for the period | 10,999 | 12,833 | 73,420 |
| of which: allocated to shareholders of the parent company | 10,975 | 12,692 | 73,192 |
| of which: allocated to non-controlling interests | 24 | 141 | 228 |
| Earnings per share (from continuing operations) | | | |
| undiluted (EUR) | 0.20 | 0.26 | 1.43 |
| diluted (EUR) | 0.20 | 0.26 | 1.40 |

Cash Flow Statement

as of March 31, 2021

| kEUR | 01.01.- 31.03.2021 | 01.01.- 31.03.2020 | 01.01.- 31.12.2020 |
|---|-----------------------|-----------------------|-----------------------|
| Consolidated net income for the period | 10,999 | 12,833 | 73,420 |
| Depreciation of property, plant and equipment and right-of-use assets and amortization of intangible assets | 26,823 | 16,782 | 75,707 |
| Earnings on sale of fixed assets | -18 | -17 | -136 |
| Change in provisions (including income tax liabilities) | -1,304 | -7,648 | 3,378 |
| Deferred tax income/expense | 724 | -176 | 6,277 |
| Other non-cash earnings/ expenditures | 2,817 | 6,512 | 3,395 |
| | 40,041 | 28,286 | 162,041 |
| Change in inventories | 3,570 | -2,080 | 9,494 |
| Change in trade receivables and other receivables | -21,059 | -25,336 | -34,823 |
| Change in income tax receivables | 1,357 | 8,843 | 3,114 |
| Change in other receivables | -12,709 | -10,885 | -2,532 |
| Change in trade payables | -10,935 | -8,469 | 11,262 |
| Change contract liabilities | 68,216 | 64,632 | -3,946 |
| Change in other liabilities | 15,338 | 10,728 | 5,322 |
| Operating cash flow | 83,819 | 65,719 | 149,931 |
| Cash inflow from disposals of intangible assets | 0 | 0 | 0 |
| Cash outflow for capital expenditure in intangible assets | -9,249 | -9,006 | -38,045 |
| Cash inflow from disposals of property, plant and equipment | 248 | 23 | 660 |
| Cash outflow for capital expenditure in property, plant and equipment | -4,413 | -5,698 | -17,684 |
| Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods) | -1,169 | -7,819 | -397,108 |
| Cash outflow for acquisitions from prior periods | 0 | -1,487 | -3,132 |
| Cash inflow from the disposal of subsidiaries and business units | 0 | 0 | 220 |
| Cash outflow for capital expenditures in joint ventures and other equity investments | 0 | 0 | -2,027 |
| Cash flow from investing activities | -14,583 | -23,987 | -457,116 |
| Cash inflow from the issue of shares | 0 | 0 | 32,686 |
| Cash inflow from the sale of treasury shares | 0 | 0 | 305,304 |
| Buyback of own shares | -41,286 | 0 | 0 |
| Dividend paid | 0 | 0 | -24,206 |
| Capital paid to non-controlling interests | 0 | 0 | -162 |
| Acquisition of additional shares from non-controlling interests | 0 | -400 | -400 |
| Downpayment of lease liabilities | -4,707 | -4,098 | -16,762 |
| Cash inflow from borrowing of loans | 42,963 | 401,857 | 489,048 |
| Cash outflow from the repayment of loans | -54,229 | -424,757 | -447,433 |
| Cash flow from financing activities | -57,259 | -27,398 | 338,073 |
| Cash and cash equivalents at the beginning of the period | 75,910 | 46,350 | 46,350 |
| Change in cash and cash equivalents | 11,977 | 14,334 | 30,888 |
| Changes due to exchange rate fluctuations | 953 | -1,603 | -1,328 |
| Cash and cash equivalents at the end of the period | 88,840 | 59,081 | 75,910 |
| Interest paid | 392 | 4,029 | 5,412 |
| Interest received | 194 | 324 | 1,432 |
| Income taxes paid | 6,079 | 6,856 | 20,554 |

Segment reporting

as of March 31, 2021

| | Segment AIS Ambulatory Information Systems | | | Segment HIS Hospital Information Systems | | | Segment CHS Consumer and Health Man- agement Information Systems | | | Segment PCS Pharmacy Information Systems | | |
|---|--|--------------------|-------------------|--|--------------------|-------------------|---|--------------------|-------------------|--|--------------------|-------------------|
| | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 |
| kEUR | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 |
| Sales to third parties | 112,250 | 95,120 | 375,204 | 55,129 | 33,670 | 186,588 | 33,669 | 25,380 | 158,399 | 27,890 | 28,802 | 116,791 |
| thereof Software license | 9,677 | 7,055 | 28,064 | 3,900 | 3,041 | 22,950 | 239 | 207 | 1,065 | 1,079 | 1,265 | 6,050 |
| thereof Hardware | 5,597 | 9,309 | 30,319 | 2,948 | 1,736 | 12,362 | 6,176 | 1,037 | 47,600 | 4,435 | 5,656 | 24,809 |
| thereof Professional Services | 8,835 | 8,659 | 32,536 | 10,684 | 7,080 | 38,067 | 2,806 | 3,043 | 18,582 | 2,463 | 2,533 | 9,686 |
| thereof Software Maintenance & hotline | 62,670 | 55,608 | 227,397 | 28,414 | 17,362 | 83,102 | 3,085 | 2,533 | 10,925 | 9,404 | 8,787 | 36,221 |
| thereof Other recurring revenues | 24,250 | 13,704 | 54,352 | 9,097 | 4,365 | 29,859 | 11,424 | 10,236 | 43,606 | 10,407 | 10,400 | 39,256 |
| thereof Advertising, eDetailing and Data | 136 | 151 | 441 | 0 | 0 | 0 | 9,627 | 7,815 | 35,947 | 70 | 184 | 767 |
| thereof Other revenue | 1,084 | 634 | 2,095 | 85 | 86 | 248 | 313 | 509 | 675 | 33 | -23 | 2 |
| Point in time of revenue recognition | | | | | | | | | | | | |
| at a specific point in time | 7,875 | 12,183 | 38,571 | 4,086 | 2,194 | 16,989 | 6,541 | 1,573 | 63,039 | 4,739 | 6,183 | 12,359 |
| over a period of time | 104,375 | 82,938 | 336,633 | 51,043 | 31,475 | 169,599 | 27,128 | 23,806 | 95,359 | 23,151 | 22,619 | 104,432 |
| | 112,250 | 95,120 | 375,204 | 55,129 | 33,670 | 186,588 | 33,669 | 25,380 | 158,399 | 27,890 | 28,802 | 116,791 |
| thereof recurring sales | 86,920 | 69,313 | 281,749 | 37,511 | 21,727 | 112,961 | 14,509 | 12,769 | 54,531 | 19,811 | 19,187 | 75,478 |
| Sales between segments | 12,144 | 7,183 | 51,365 | 1,532 | 1,489 | 6,066 | 3,361 | 2,580 | 19,036 | 799 | 835 | 5,953 |
| Segment Sales | 124,394 | 102,303 | 426,569 | 56,661 | 35,158 | 192,654 | 37,029 | 27,960 | 177,435 | 28,689 | 29,637 | 122,744 |
| Capitalized inhouse services | 1,735 | 2,561 | 8,119 | 3,846 | 2,942 | 13,155 | 1,499 | 1,612 | 7,011 | 797 | 684 | 2,650 |
| Other income | 1,404 | 694 | 6,179 | 342 | 1,248 | 2,743 | 336 | 444 | 1,569 | 562 | 279 | 1,102 |
| Expenses for goods and ser- vices purchased | -26,563 | -22,473 | -99,891 | -10,691 | -5,296 | -37,831 | -16,111 | -9,342 | -68,020 | -7,113 | -7,472 | -32,762 |
| Personnel costs | -50,572 | -38,727 | -150,053 | -31,512 | -21,450 | -102,985 | -10,074 | -8,632 | -36,450 | -10,473 | -10,035 | -41,381 |
| Other expenses | -20,679 | -17,234 | -73,189 | -11,020 | -8,391 | -38,862 | -7,476 | -6,794 | -32,883 | -4,483 | -4,236 | -18,854 |
| EBITDA | 29,719 | 27,124 | 117,733 | 7,626 | 4,211 | 28,874 | 5,204 | 5,248 | 48,662 | 7,978 | 8,857 | 33,499 |
| in % of sales | 26.5% | 28.5% | 31.4% | 13.8% | 12.5% | 15.5% | 15.5% | 20.7% | 30.7% | 28.6% | 30.7% | 28.7% |
| Depreciation of property, plant and equipment and right-of-use assets | | | | | | | | | | | | |
| Amortization of intangible assets | | | | | | | | | | | | |
| EBIT | | | | | | | | | | | | |
| Results from associates recog- nised at equity | | | | | | | | | | | | |
| Financial income | | | | | | | | | | | | |
| Financial expense | | | | | | | | | | | | |
| EBT | | | | | | | | | | | | |
| Taxes on income for the period | | | | | | | | | | | | |
| Profit for the period from dis- continued operations | | | | | | | | | | | | |
| Consolidated net income for the period | | | | | | | | | | | | |
| in % of sales | | | | | | | | | | | | |

| | All other Segments | | | Sum Segments | | | Consolidation | | | CGM Group | | |
|---|--------------------|-----------------|----------------|-----------------|-----------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|
| | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 | 2021 | 2020 | 2020 |
| kEUR | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 | 01.01. - 31.03. | 01.01. - 31.03. | 01.01. - 31.12 |
| Sales to third parties | 0 | 171 | 277 | 228,937 | 183,143 | 837,259 | 0 | 0 | 0 | 228,937 | 183,143 | 837,259 |
| thereof Software license | 0 | 1 | 3 | 14,895 | 11,570 | 58,131 | 0 | 0 | 0 | 14,895 | 11,570 | 58,131 |
| thereof Hardware | 0 | 0 | 0 | 19,155 | 17,739 | 115,090 | 0 | 0 | 0 | 19,155 | 17,739 | 115,090 |
| thereof Professional Services | 0 | 170 | 239 | 24,788 | 21,484 | 99,110 | 0 | 0 | 0 | 24,788 | 21,484 | 99,110 |
| thereof Software Maintenance & hotline | 0 | 0 | 0 | 103,573 | 84,290 | 357,645 | 0 | 0 | 0 | 103,573 | 84,290 | 357,645 |
| thereof Other recurring revenues | 0 | 0 | 0 | 55,178 | 38,706 | 167,073 | 0 | 0 | 0 | 55,178 | 38,706 | 167,073 |
| thereof Advertising, eDetailing and Data | 0 | 0 | 0 | 9,833 | 8,149 | 37,155 | 0 | 0 | 0 | 9,833 | 8,149 | 37,155 |
| thereof Other revenue | 0 | 0 | 36 | 1,516 | 1,206 | 3,055 | 0 | 0 | 0 | 1,516 | 1,206 | 3,055 |
| Point in time of revenue recognition | | | | | | | | | | | | |
| at a specific point in time | 0 | 0 | 36 | 23,240 | 22,134 | 130,994 | 0 | 0 | 0 | 23,240 | 22,134 | 130,994 |
| over a period of time | 0 | 171 | 241 | 205,697 | 161,009 | 706,265 | 0 | 0 | 0 | 205,697 | 161,009 | 706,265 |
| | 0 | 171 | 277 | 228,937 | 183,143 | 837,259 | 0 | 0 | 0 | 228,937 | 183,143 | 837,259 |
| thereof recurring sales | 0 | 0 | 0 | 158,751 | 122,996 | 524,718 | 0 | 0 | 0 | 158,751 | 122,996 | 524,718 |
| Sales between segments | 4,891 | 4,987 | 18,321 | 22,728 | 17,073 | 100,740 | -22,728 | -17,073 | -100,740 | 0 | 0 | 0 |
| Segment Sales | 4,891 | 5,159 | 18,598 | 251,665 | 200,216 | 937,999 | -22,728 | -17,073 | -100,740 | 228,937 | 183,143 | 837,259 |
| Capitalized inhouse services | 0 | 223 | 937 | 7,877 | 8,022 | 31,872 | 0 | 0 | 0 | 7,877 | 8,022 | 31,872 |
| Other income | 19,035 | 12,395 | 59,072 | 21,678 | 15,060 | 70,665 | -19,291 | -13,287 | -60,103 | 2,387 | 1,773 | 10,562 |
| Expenses for goods and services purchased | -713 | -633 | -2,761 | -61,189 | -45,216 | -241,265 | 19,737 | 13,047 | 85,087 | -41,452 | -32,170 | -156,178 |
| Personnel costs | -12,028 | -8,976 | -48,023 | -114,660 | -87,821 | -378,893 | 179 | -1,787 | 1,841 | -114,481 | -89,607 | -377,052 |
| Other expenses | -17,272 | -13,647 | -58,622 | -60,931 | -50,301 | -222,410 | 22,035 | 19,250 | 73,423 | -38,896 | -31,051 | -148,987 |
| EBITDA | -6,088 | -5,479 | -30,799 | 44,440 | 39,960 | 197,969 | -68 | 150 | -493 | 44,372 | 40,110 | 197,476 |
| in % of sales | | | | 19.4% | 21.8% | 23.6% | | | | 19.4% | 21.9% | 23.6% |
| Depreciation of property, plant and equipment and right-of-use assets | | | | | | | | | | -8,288 | -7,397 | -30,856 |
| Amortization of intangible assets | | | | | | | | | | -18,535 | -9,385 | -44,851 |
| EBIT | | | | | | | | | | 17,549 | 23,328 | 121,769 |
| Results from associates recognised at equity | | | | | | | | | | 11 | -603 | -931 |
| Financial income | | | | | | | | | | 160 | 620 | 2,651 |
| Financial expense | | | | | | | | | | -1,640 | -4,536 | -13,063 |
| EBT | | | | | | | | | | 16,080 | 18,809 | 110,426 |
| Taxes on income for the period | | | | | | | | | | -5,081 | -5,976 | -37,006 |
| Profit for the period from discontinued operations | | | | | | | | | | 0 | 0 | 0 |
| Consolidated net income for the period | | | | | | | | | | 10,999 | 12,833 | 73,420 |
| in % of sales | | | | | | | | | | 4.8% | 7.0% | 8.8% |

Additional Information

FINANCIAL CALENDAR

May 19, 2021 - Annual General Meeting 2021
August 5, 2021 - Interim Report Q2 2021
September 15, 2021 - Capital Markets Day
November 4, 2021 - Interim Report Q3 2021

CONTACT INFORMATION

CompuGroup Medical SE & Co. KGaA
Investor Relations
Maria Trost 21
56070 Koblenz

Telephone: +49 (0) 261 8000-7030
Fax: +49 (0) 261 8000-3200

E-Mail: investor@cgm.com
www.cgm.com

Management Responsibility Statement

To the best of our knowledge, and in accordance with applicable accounting principles for interim financial reporting, the consolidated interim financial statements give a true and fair view of the net assets, financial position and results of operations of the Group, and the Group interim management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group over the remainder of the financial year.

Koblenz, May 6, 2021

CompuGroup Medical SE & Co. KGaA

Represented by the Managing Directors of
CompuGroup Medical Management SE



Dr. Dirk Wössner



Frank Brecher



Dr. Ralph Körfgen



Dr. Eckart Pech



Michael Rauch



Hannes Reichl

CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany

Synchronizing Healthcare

